Literature DB >> 23704552

Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".

Nicholas F Fitz1, Andrea A Cronican, Iliya Lefterov, Radosveta Koldamova.   

Abstract

Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrated in a mouse model for Alzheimer's disease (AD) that treatment of APP/PS1ΔE9 mice with bexarotene decreased Aβ pathology and ameliorated memory deficits. We confirm the reversal of memory deficits in APP/PS1ΔE9 mice expressing human APOE3 or APOE4 to the levels of their nontransgenic controls and the significant decrease of interstitial fluid Aβ, but not the effects on amyloid deposition.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23704552      PMCID： PMC4086452          DOI： 10.1126/science.1235809

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  14 in total

1.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 2.  The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration.

Authors:  Radosveta Koldamova; Nicholas F Fitz; Iliya Lefterov
Journal:  Biochim Biophys Acta       Date:  2010-02-24

Review 3.  Apolipoprotein E in Alzheimer's disease and other neurological disorders.

Authors:  Philip B Verghese; Joseph M Castellano; David M Holtzman
Journal:  Lancet Neurol       Date:  2011-03       Impact factor: 44.182

Review 4.  Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach.

Authors:  Radosveta Koldamova; Iliya Lefterov
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

5.  ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.

Authors:  Paige E Cramer; John R Cirrito; Daniel W Wesson; C Y Daniel Lee; J Colleen Karlo; Adriana E Zinn; Brad T Casali; Jessica L Restivo; Whitney D Goebel; Michael J James; Kurt R Brunden; Donald A Wilson; Gary E Landreth
Journal:  Science       Date:  2012-02-09       Impact factor: 47.728

Review 6.  The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents.

Authors:  Ekrem Dere; Joseph P Huston; Maria A De Souza Silva
Journal:  Neurosci Biobehav Rev       Date:  2007-02-12       Impact factor: 8.989

Review 7.  The role of apolipoprotein E in Alzheimer's disease.

Authors:  Jungsu Kim; Jacob M Basak; David M Holtzman
Journal:  Neuron       Date:  2009-08-13       Impact factor: 17.173

8.  Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.

Authors:  Nicholas F Fitz; Andrea Cronican; Tam Pham; Allison Fogg; Abdul H Fauq; Robert Chapman; Iliya Lefterov; Radosveta Koldamova
Journal:  J Neurosci       Date:  2010-05-19       Impact factor: 6.167

9.  The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease.

Authors:  Radosveta P Koldamova; Iliya M Lefterov; Matthias Staufenbiel; Darren Wolfe; Shaohua Huang; Joseph C Glorioso; Michael Walter; Michael G Roth; John S Lazo
Journal:  J Biol Chem       Date:  2004-11-22       Impact factor: 5.157

10.  Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers.

Authors:  Iliya Lefterov; Nicholas F Fitz; Andrea Cronican; Preslav Lefterov; Matthias Staufenbiel; Radosveta Koldamova
Journal:  ASN Neuro       Date:  2009-04-30       Impact factor: 4.146
View more
  86 in total

1.  Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases.

Authors:  Javier Riancho; Maria T Berciano; Jose Berciano; Miguel Lafarga
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

Review 2.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 3.  Therapeutic potential of nuclear receptor agonists in Alzheimer's disease.

Authors:  Miguel Moutinho; Gary E Landreth
Journal:  J Lipid Res       Date:  2017-03-06       Impact factor: 5.922

Review 4.  Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.

Authors:  Catherine Bowes Rickman; Sina Farsiu; Cynthia A Toth; Mikael Klingeborn
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-13       Impact factor: 4.799

5.  Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's β-amyloid peptides.

Authors:  Jacques Fantini; Coralie Di Scala; Nouara Yahi; Jean-Denis Troadec; Kevin Sadelli; Henri Chahinian; Nicolas Garmy
Journal:  ACS Chem Neurosci       Date:  2014-01-12       Impact factor: 4.418

6.  CSF Apo-E levels associate with cognitive decline and MRI changes.

Authors:  Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-03       Impact factor: 17.088

7.  Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy.

Authors:  Valerie Bomben; Jerrah Holth; John Reed; Paige Cramer; Gary Landreth; Jeffrey Noebels
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

8.  Preclinical data reproducibility for R&D--the challenge for neuroscience.

Authors:  Thomas Steckler
Journal:  Psychopharmacology (Berl)       Date:  2015-01-14       Impact factor: 4.530

9.  PPARδ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis.

Authors:  Audrey S Dickey; Dafne N Sanchez; Martin Arreola; Kunal R Sampat; Weiwei Fan; Nicolas Arbez; Sergey Akimov; Michael J Van Kanegan; Kohta Ohnishi; Stephen K Gilmore-Hall; April L Flores; Janice M Nguyen; Nicole Lomas; Cynthia L Hsu; Donald C Lo; Christopher A Ross; Eliezer Masliah; Ronald M Evans; Albert R La Spada
Journal:  Sci Transl Med       Date:  2017-12-06       Impact factor: 17.956

10.  Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.

Authors:  Jenny U Johansson; Nathaniel S Woodling; Qian Wang; Maharshi Panchal; Xibin Liang; Angel Trueba-Saiz; Holden D Brown; Siddhita D Mhatre; Taylor Loui; Katrin I Andreasson
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.